Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 40Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 3Resectable Pancreatic Cancer 2Rectal Neoplasms 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Urachal cancer 1Stomach Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cancer Metastatic 1Pancreatic Adenocarcinoma 1Neoplasms, Basal Cell 1Locally Advanced Pancreatic Adenocarcinoma 1Localized Pancreatic Adenocarcinoma 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Ampullary Adenocarcinoma 1

Interventions

Gemcitabine 2selinexor 1ponatinib 1neratinib 1folfirinox 1contrast agent BR1 1cobimetinib 1ceritinib 1brigatinib 1abemaciclib 1Urination 1S 1 (combination) 1Radiotherapy 1Radiosurgery 1Practice Guidelines as Topic 1Pancreaticoduodenectomy 1Paclitaxel 1Oxaliplatin 1Long Interspersed Nucleotide Elements 1Laparoscopy 1Irinotecan 1Immunotherapy, Adoptive 1Floxuridine 1Etoposide 1Endosonography 1Endoscopic Ultrasound-Guided Fine Needle Aspiration 1Drug Therapy 1Doxorubicin 1Colchicine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Pancreatic Ductal × folfirinox × Clear all
NCT02243007 2017-05-16

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Terminated
7 enrolled 8 charts
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡